ATE226449T1 - Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen - Google Patents

Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen

Info

Publication number
ATE226449T1
ATE226449T1 AT99964038T AT99964038T ATE226449T1 AT E226449 T1 ATE226449 T1 AT E226449T1 AT 99964038 T AT99964038 T AT 99964038T AT 99964038 T AT99964038 T AT 99964038T AT E226449 T1 ATE226449 T1 AT E226449T1
Authority
AT
Austria
Prior art keywords
pharmaceutical preparations
associated virus
excipients
compositions
produced therefrom
Prior art date
Application number
AT99964038T
Other languages
English (en)
Inventor
Hema S Sista
Yero J Espinoza
Original Assignee
Avigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avigen Inc filed Critical Avigen Inc
Application granted granted Critical
Publication of ATE226449T1 publication Critical patent/ATE226449T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT99964038T 1998-12-03 1999-12-02 Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen ATE226449T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11068998P 1998-12-03 1998-12-03
PCT/US1999/028460 WO2000032233A2 (en) 1998-12-03 1999-12-02 Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith

Publications (1)

Publication Number Publication Date
ATE226449T1 true ATE226449T1 (de) 2002-11-15

Family

ID=22334360

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99964038T ATE226449T1 (de) 1998-12-03 1999-12-02 Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen

Country Status (9)

Country Link
EP (1) EP1144009B1 (de)
JP (5) JP2002531418A (de)
AT (1) ATE226449T1 (de)
AU (2) AU773834B2 (de)
CA (1) CA2353417C (de)
DE (1) DE69903666T2 (de)
ES (1) ES2185417T3 (de)
PT (1) PT1144009E (de)
WO (1) WO2000032233A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2442284C (en) * 2001-04-04 2009-10-06 Delsitech Oy Biodegradable carrier and method for preparation thereof
JP2005517394A (ja) 2001-12-12 2005-06-16 エフ エイチ フォールディング アンド カンパニー リミテッド ウイルス保存のための組成物
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
EP2816118B1 (de) 2005-05-31 2018-10-17 The Regents of the University of Colorado, a body corporate Verfahren zur Bereitstellung von Genen
DK2350271T3 (en) * 2008-11-20 2016-04-04 Biogen Ma Inc ARGININ INACTIVATION OF ENVIRONMENT VIRA
CA2856137A1 (en) 2011-11-22 2013-05-30 The Children's Hospital Of Philadelphia Virus vectors for highly efficient transgene delivery
EP4008356A1 (de) 2016-03-31 2022-06-08 University of Cincinnati Verfahren und zusammensetzungen zur behandlung von als
US20190185864A1 (en) 2016-08-23 2019-06-20 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
US11179411B2 (en) 2017-05-18 2021-11-23 Kyoto University Composition for prevention or treatment of spinocerebellar ataxia type 36
EP3720500A4 (de) * 2017-12-05 2021-08-25 Applied Genetic Technologies Corporation Formulierungsoptimierung für virale partikel
US20220325250A1 (en) 2019-08-14 2022-10-13 Leukocare Ag Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
EP4114958A1 (de) 2020-02-21 2023-01-11 Akouos, Inc. Zusammensetzungen und verfahren zur behandlung von nicht altersbedingten hörschäden bei einer person

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
FR2751343B1 (fr) * 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
JP2001500376A (ja) * 1996-09-06 2001-01-16 カイロン コーポレイション 組換えaavベクターを使用する治療分子の肝臓特異的送達のための方法および組成物

Also Published As

Publication number Publication date
DE69903666T2 (de) 2003-07-03
JP5663285B2 (ja) 2015-02-04
WO2000032233A3 (en) 2001-10-18
PT1144009E (pt) 2003-01-31
CA2353417A1 (en) 2000-06-08
WO2000032233A2 (en) 2000-06-08
JP2017206556A (ja) 2017-11-24
EP1144009B1 (de) 2002-10-23
JP2011046748A (ja) 2011-03-10
CA2353417C (en) 2008-04-22
AU2036100A (en) 2000-06-19
ES2185417T3 (es) 2003-04-16
JP2016040330A (ja) 2016-03-24
EP1144009A2 (de) 2001-10-17
JP2002531418A (ja) 2002-09-24
EP1144009A3 (de) 2002-02-06
DE69903666D1 (de) 2002-11-28
JP2014058578A (ja) 2014-04-03
AU2004205308A1 (en) 2004-09-23
AU773834B2 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
ATE226449T1 (de) Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen
DE69940354D1 (de) Adenovirus-formulierungen zur gentherapie
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
HUP0002877A2 (hu) Stabil inzulinkészítmények és eljárás előállításukra
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
DE59410380D1 (de) Endosomolytisch wirksame partikel
MY150893A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
DE60033437D1 (de) Glp-2 enthaltende formulierungen
EP0710288A4 (de) Adenovirale vektoren für die behandlung der hämophilie
LU92749I2 (fr) Composition comprenant le virus de la diarrhée virale bovine atténué 1(bvdv-1) et le virus de la diarrhée virale bovine atténué 2 (bvdv-2)
FR2716893B1 (fr) Virus recombinants, leur préparation et leur utilisation thérapeutique.
WO2002060926A3 (en) Hepatitis c tripeptide inhibitors
ATE206308T1 (de) Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
NO905438L (no) Virusmiddel.
FR2704556B1 (fr) Virus recombinants et leur utilisation en thérapie génique.
PT935609E (pt) Composicoes cristalizaveis que contem um complexo entre o dominio de protease ns3 do virus da hepatite c e ns4a cristais resultantes
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
BR9911040A (pt) 2-fenil-1-[4-(2-aminoetóxi)-benzil]-indol em combinação com estrogêneos
DK0921812T3 (da) Insulinpræparater, som indeholder NaCi
AU2003235764A8 (en) Viruses with enhanced lytic potency
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
DE69736779D1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
ATE303816T1 (de) Neue therapeutische verwendung eines eine virale ansteckung modulierendes protein zur verhinderung von abstossung von fremdtransplantaten
BR9903567A (pt) "composições pesticidas"
DE69518319T2 (de) Verwendung von oberflächenaktiven substanzen zur stabilisierung von peptiden und proteinen zur radiopharmazeutischen verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties